blood cancer

Early Treatment Delay Progression of Blood Cell Cancer

harminka — Fri, 07 Nov 2008 05:10:58 -0600

Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer. They have found that the use of predictive biomarkers along with two targeted treatments significantly delays the need for conventional chemotherapy in patients with early-stage, but high-risk, chronic lymphoid leukemia (CLL).

Silencing a protein could kill T-Cells, reverse leukemia

harminka — Thu, 23 Oct 2008 10:12:56 -0500

Blocking the signals from a protein that activates cells in the immune system could help kill cells that cause a rare form of blood cancer, according to physicists and oncologists who combined computer modeling and molecular biology in their discovery.

Methadone breaks resistance in untreatable forms of leukemia

harminka — Fri, 01 Aug 2008 08:04:45 -0500

Researchers in Germany have discovered that methadone, an agent used to break addiction to opioid drugs, has surprising killing power against leukemia cells, including treatment resistant forms of the cancer.

Sparing leukemia Patients from unnecessary treatment

harminka — Wed, 30 Jul 2008 01:26:22 -0500

Nearly a third of leukemia patients do not respond to chemotherapy, but this is not usually discovered until they have already endured a week-long chemotherapy treatment and waited a month to see whether it has worked. A new study shows that PET scans could tell how well a patient is responding after just one day of chemotherapy.

Gene mutation improves leukemia drug's effect

harminka — Wed, 18 Jun 2008 08:40:25 -0500

Gene mutations that make cells cancerous can sometimes also make them more sensitive to chemotherapy. A new study led by cancer researchers at Ohio State University shows that a mutation present in some cases of acute leukemia makes the disease more susceptible to high doses of a particular anticancer drug.

Microenvironment main driver of aggressive multi-lineage leukemia disease type

harminka — Tue, 10 Jun 2008 14:18:34 -0500

Research led by scientists at Cincinnati Children's Hospital Medical Center has revealed new clues into what causes different types of a particularly aggressive group of blood cancers known as mixed lineage leukemias (MLL) and how the disease might be treated, according to a study in the June 9 issue of Cancer Cell.

Biological and clinical activity in relapsed leukemia patients

harminka — Thu, 05 Jun 2008 00:50:38 -0500

Finbarr Cotter, M.D., Ph.D., Professor of the Institute of Cell and Molecular Science at Barts and The London School of Medicine, today presented in an oral session "Clinical Caspase Activation in CLL by GCS-100: a Phase 2 Study" at the 10th International Conference on Malignant Lymphoma (10-ICML).

Arsenic-based therapy shown to help eradicate leukemia-initiating cells

harminka — Mon, 12 May 2008 11:22:43 -0500

In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies.

New lymphoma therapies targets diverse and difficult cancer

harminka — Fri, 25 Apr 2008 09:33:01 -0500

The fifth leading cause of cancer in the United States, lymphoma is made up of more than 40 rare and highly diverse diseases that target the body's lymphatic system. Lymphomas include both one of the fastest growing cancers -- Burkitt's lymphoma, which can double in size in as little as a day -- and one of the slowest, chronic lymphocytic leukemia (CLL).

Two suppressor molecules affect 70 genes in leukemia

harminka — Fri, 25 Apr 2008 06:27:12 -0500

By restoring two small molecules that are often lost in chronic leukemia, researchers were able to block tumor growth in an animal model.

Genetic basis of resistance to chemotherapy in children with acute leukemia

harminka — Tue, 15 Apr 2008 13:14:11 -0500

In a new study published in PLoS Medicine, William Evans of St Jude Children’s Research Hospital, Memphis, and colleagues provide new insight into resistance to the widely-used cancer drug methotrexate (MTX) in patients with acute lymphoblastic leukaemia (ALL), the most common cancer in children.

New avenues to understanding an aggressive form of leukemia

harminka — Mon, 14 Apr 2008 13:51:41 -0500

Researchers at St. Jude ChildrenЎ¦s Research Hospital have discovered evidence that a series of genetic mutations work together to initiate most cases of an aggressive and often-fatal form of acute lymphoblastic leukemia (ALL).